OrbiMed β Full Portfolio
275 tracked investments Β· page 1 of 2 Β· listed companies and verified rows first
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)Vijay Pande(Director)
Aadi Bioscience is a commercial-stage biopharmaceutical company developing therapies for cancer patients with mTOR pathway driver alterations, with an initial focus on advanced malignant PEComa, an ultra-rare cancer.
BiotechHealthtechMorristown, US
Baiteng Zhao(Director)Scott Giacobello(Executive Officer)Caley Castelein(Director)Richard Maroun(Director)Bryan Ball(Executive Officer)Behzad Aghazadeh(Director)
Board seatChau KhuongΒ· per SEC Form D Β· $41.8M raise Β· filed Mar 2017
BiotechMenlo Park, US
Nathan Hubbard(Executive Officer)Aya Jakobovits(Executive Officer, Director)Jonathan Silverstein(Director)Carl Gordon(Director)Florent Gros(Director)Erez Chimovits(Director)
Board seatJonathan SilversteinCarl GordonΒ· per SEC Form D
Arvinas is a clinical-stage biopharmaceutical company developing PROTAC protein degrader therapies for oncology and neurology.
BiotechNew Haven, US
Stephen Squinto(Director)Liam Ratcliffe(Director)Andrew Levin(Director)Sean Cassidy(Executive Officer)Jonathan Soderstrom(Director)Brad Margus(Director)
Board seatStephen SquintoΒ· per SEC Form D Β· $55M raise Β· filed Apr 2018
BiotechLa Jolla, US
Eric W. Roberts(Executive Officer, Director)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Kenneth A. Stauderman(Executive Officer)Sudarshan Hebbar(Executive Officer)Eric Bjerkholt(Director)
Board seatChau KhuongΒ· per SEC Form D Β· $80M raise Β· filed Aug 2019
BiotechTel Aviv
Neil Harris Cohen(Director)Jill Quigley(Director)Sigal Fattal(Executive Officer)Adi Mor(Executive Officer, Director)Alan Charles Moses(Director)Matthew Frankel(Executive Officer)
Board seatStephen SquintoΒ· per SEC Form D Β· $45.4M raise Β· filed Mar 2021
Cambridge, US
Board seatStephen SquintoCarl GordonΒ· per SEC Form D
BiotechCambridge, US
Sara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)Mette Kirstine Agger(Director)James G. McArthur(Executive Officer, Director)
Board seatDavid BonitaΒ· per SEC Form D Β· $63M raise Β· filed Mar 2019
BiotechLexington, US
Jasbir S. Seehra(Executive Officer, Director)Julius Knowles(Director)Alon Lazarus(Director)Ohad Hammer(Director)Ran Nussbaum(Director)
Board seatCarl GordonΒ· per SEC Form D Β· $56M raise Β· filed Mar 2020
BiotechAustin, US
Matthew Winkler(Director)Michael Powell(Director)Clay Siegall(Director)Sinil Kim(Executive Officer)Paul Lammers(Executive Officer, Director)Jon Irvin(Executive Officer)
Board seatChau KhuongΒ· per SEC Form D Β· $80M raise Β· filed Jun 2019
Prelude Therapeutics develops precision oncology medicines, including selective KAT6A degraders, mutant-selective JAK2 inhibitors, and degrader antibody conjugates for cancer treatment.
AI & Machine LearningBiotechMedical DevicesNewark, US
Krishna Vaddi(Executive Officer, Director)Paul Friedman(Director of Issuer)
Board seatDavid BonitaΒ· per SEC Form D
BiotechBoston, US
Edward T. Mathers(Director)David J. McGirr(Director)Jonathan Silverstein(Director)Keith Gottesdiener(Executive Officer, Director)David P. Meeker, M.D.(Director)Neil Exter(Director)
Board seatJonathan SilversteinΒ· per SEC Form D Β· $40M raise Β· filed Dec 2015
San Jose, US
Jeffrey W. Dunn(Executive Officer, Director)Mark Reiley(Director)Timothy E. Davis(Director)John G. Freund(Director)David Bonita(Director)Karen A. Licitra(Director)
Board seatDavid BonitaΒ· per SEC Form D Β· $21M raise Β· filed Jun 2016
BiotechSouth San Francisco, US
Kirk Ways(Director)Javier Szwarcberg(Executive Officer, Director)Simpson Camilla(Director)Percival Barretto-Ko(Director)Tiba Aynechi(Director)Samir Gharib(Executive Officer)
Board seatDina ChayaΒ· per SEC Form D Β· $53.6M raise Β· filed Feb 2023
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Ed Mathers(Director)Chau Khuong(Director)Bharatt Chowrira(Executive Officer)Ankit Mahadevia(Director)Michael Sheahan(Executive Officer)Peter Barrett(Director)
Board seatChau KhuongΒ· per SEC Form D Β· $42M raise Β· filed May 2017
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Timothy Mayer(Executive Officer)Michael Richman(Executive Officer, Director)Elaine V. Jones(Director)Udayan Guha(Executive Officer)Anne Borgman(Director)Steven P. Cobourn(Executive Officer)
Board seatChau KhuongΒ· per SEC Form D Β· $93.4M raise Β· filed Nov 2018
Adaptive Biotechnologies decodes the genetic patterns of the adaptive immune system to develop clinical products for diagnosing and treating disease.
BiotechDigital HealthHealthtechMedical DevicesSeattle, US
Arnold Levine(Director)Chad Robins(Executive Officer, Director)Andris Zoltners(Director)Tom Willis(Director)Kathleen Determann(Executive Officer)Peter Neupert(Director)
Clinical-stage biopharmaceutical company focused on identifying, developing and commercializing differentiated medicines for cancer patients.
BiotechMedical DevicesNewtown Square, US
Brent Rice(Chief Commercial Officer)Jason Zhang(Director)Cong Xu(Director)Zhengbin (Bing) Yao(Executive Officer, Director)Stuart Lutzker(Director)
Aura Biosciences develops targeted oncology therapies based on a virus-like drug conjugate (VDC) technology platform, aimed at cancers with high unmet need.
BiotechMedical DevicesCambridge, US
Raj Parekh, Ph.D.(Director)Michael Wyzga(Executive Officer)Joel Jean-Mairet, Ph.D.(Director)Jose' Baselga, Ph.D.(Director)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)
AVITA Medical develops therapeutic acute wound care technologies, including the FDA-approved RECELL System that uses a patient's own skin to create a Spray-On Skin cell suspension for treating thermal burn wounds and full-thickness skin defects.
BiotechHealthtechMedical Devices
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Eric Morgen(Director)Dov Goldstein(Executive Officer)Jason Coloma(Director)Kristen Fortney(Executive Officer, Director)
Caris Lifesciences operates a precision oncology platform that analyzes DNA, RNA and proteins across tissue and blood to profile a patient's cancer and match treatments and clinical trials.
AI & Machine LearningBiotechHealthtech
David Dean Halbert(Chairman, Founder and CEO)
BiotechGaithersburg, US
George J. Joulwan(Director)Robert G Kramer(Executive Officer)Ronald B Richard(Director)Katherine Strei(Executive Officer)Fuad El-Hibri(Director, Executive Officer)Adam R Havey(Executive Officer)
Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
BiotechDigital HealthHealthtechMedical Devices<UNKNOWN>, US
BiotechHealthtechMiami, US
Raymond Cohen(Director)Thomas J. Kester(Director)Scott R. Ward(Director)Patrick Verta(Executive Officer)Kathryn Arnold(Director)Pete Ligotti(Executive Officer)
BiotechAustin, US
Walter Loewenbaum(Director)Josiah Hornblower(President/CEO)
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergTIMOTHY BARBERICH(Director)ALISON LAWTON(Director)ERIC ROWINSKY(Director)BRUCE WENDEL(Director)GINA CONSYLMAN(Director)
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices<UNKNOWN>, US
AndrΓ©s Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)
i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases.
BiotechDeep TechHealthtech
OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.
BiotechMedical DevicesNew York, US
Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)
HealthtechCarlsbad, US
Aditya Puri(Director)Steven Hochberg(Director)Vince Burgess(Director)David Bonita(Director)Christoph Scharf(Director)Randy Werneth(Executive Officer, Director)
Board seatDavid BonitaΒ· per SEC Form D
BiotechFoster City, US
Maneesh Jain(Director, Promoter)Daniel Diniz De Carvalho(Executive Officer, Promoter)Anne-Renee Hartman(Executive Officer)Alan Williams(Executive Officer)Lisa Alderson(Executive Officer, Director)Priscilla Huang(Executive Officer)
Board seatDavid BonitaΒ· per SEC Form D Β· $5M raise Β· filed Apr 2026
BiotechCincinnati, US
Reinhard Ambros(Director)Duane Nash(Director)Paul Weiss(Director)Muneer Satter(Director)Adrienne Graves(Director)Joseph H. Gardner(Executive Officer)
Board seatChau KhuongΒ· per SEC Form D Β· $9.2M raise Β· filed Apr 2016
Clinical-stage company developing novel treatment for recurrent high-grade gliomas
HealthtechChanhassen, US
Klaus Veitinger(Director)Imran Eba(Executive Officer)Conrad Wang(Director)Juan-Pablo Mas(Director)Jeremy Ling(Executive Officer)Robert Stein(Director)
Board seatKlaus VeitingerΒ· per SEC Form D Β· $67M raise Β· filed Jul 2026
Angiex is a biotech company developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) that target the intracellular transporter TM4SF1, which is expressed across solid cancers.
BiotechHealthtechMedical DevicesCambridge, US
Jonathan Adams(Director)Errik Anderson(Director)Jason Camm(Director)Fabian Hansen(Director)Paul Jaminet(Executive Officer, Director)Amal Amin(Director)
Board seatIain DukesΒ· per SEC Form D Β· $28.4M raise Β· filed Sep 2025
BiotechSan Francisco, US
Jonathan Silverstein(Director)Steve Squinto(Director)Kush Parmar(Director)Jonathan Leff(Director)Matthew Patterson(Executive Officer, Director)Thomas Woiwode(Director)
Board seatJonathan SilversteinΒ· per SEC Form D Β· filed Sep 2015
HealthtechWatertown, US
Thomas Barnes(Chief Executive Officer/President)Roy Amariglio(Director)Nick Olsen(Director)Stephen Squinto(Director)Richard Morris(Chief Financial Officer)Michal Silverberg(Director)
Board seatStephen SquintoΒ· per SEC Form D Β· $85M raise Β· filed Mar 2026
New York, US
Tania Dimitrova(Executive Officer)Megan Dow(Executive Officer)StJohn Donnie McGrath(Executive Officer, Director)
BoardBo Chen(Director)Carl Gordon(Director)David Wang(Director)
Board seatCarl GordonΒ· per SEC Form D Β· $55M raise Β· filed Jul 2024
BiotechLaval
Francois Desjardins(Vice President, Finance)Denis Garceau(Senior Vice President, Drug Development)Franklin Berger(Director)Roberto Bellini(President and Chief Executive Officer)Joseph Rus(Director)Youssef L. Bennani(Director)
Board seatChau KhuongΒ· per SEC Form D Β· $24M raise Β· filed Jan 2019
BiotechWestminster, US
Andrew J. Tofe(Director)Britt Pearson(Executive Officer)Jonathan Silverstein(Director)Chau Khuong(Director)Jeff Marx(Executive Officer)Glen Kashuba(Executive Officer, Director)
Board seatChau KhuongJonathan SilversteinΒ· per SEC Form D Β· $4M raise Β· filed Feb 2015
BiotechDorval
Francois Nader(Director)Donna Roy Grogan(Executive Officer)Jean-Francois Pariseau(Executive Officer, Director)Michael Singer(Executive Officer)David P. Bonita(Director)Robert Heft(Director)
Board seatDavid BonitaΒ· per SEC Form D Β· $60M raise Β· filed Jul 2015
Bothell, US
Board seatTal ZaksΒ· per SEC Form D Β· $84.8M raise Β· filed Mar 2025
La Jolla, US
Board seatStephen SquintoΒ· per SEC Form D Β· $15M raise Β· filed Sep 2025
BiotechPhiladelphia, US
Kim Blackwell(Director)Michael Byrnes(Director)Erez Chimovits(Director)Giovanni Mariggi(Director)Dieter Weinand(Director)William Hinshaw(Executive Officer, Director)
Board seatErez ChimovitsΒ· per SEC Form D Β· $46M raise Β· filed May 2025
BiotechCambridge, US
James McLaughlin(Executive Officer, Director)Jason Rhodes(Director)Carl Gordon(Director)
BoardJean George(Director)
Board seatCarl GordonΒ· per SEC Form D Β· $2M raise Β· filed May 2016
BiotechPennington, US
Chris Duke(Mr. Duke is the Chief Operating Officer of the Issuer.)Chau Khuong(Director)Gary Sender(Director)Stephen Squinto(Executive Officer, Director, Promoter)Dale Ludwig(Mr. Ludwig is the Chief Scientific Officer)Julie Hambleton(Director)
Board seatChau KhuongΒ· per SEC Form D Β· $55M raise Β· filed Dec 2021
BiotechBurlingame, US
Robert Schreiber(Director)John Celebi(Executive Officer)John Diekman(Director)Mark Goldsmith(Director)Carl Gordon(Director)David Goeddel(Director)
Board seatCarl GordonΒ· per SEC Form D Β· $6.3M raise Β· filed Jan 2015
BiotechBoston, US
Richard Wooster(Director)Jotin Marango(Executive Officer)Jean-Francois Formela(Director)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Owen Hughes(Director)
Board seatIain DukesDavid BonitaΒ· per SEC Form D Β· $75M raise Β· filed Jul 2025
Healthtech
Jerry Griffin(Director)Timothy Herbert(Executive Officer, Director)Gary Brothers(Director)Mudit Jain(Director)Marilyn Nelson(Director)Joyce Erony(Director)
Board seatChau KhuongΒ· per SEC Form D Β· $37.5M raise Β· filed Nov 2016
Woburn, US
Board seatKevin KochKlaus VeitingerΒ· per SEC Form D Β· filed Jul 2021
Pleasanton, US
Board seatChau KhuongΒ· per SEC Form D Β· $17M raise Β· filed Jan 2021
San Francisco, US
Chau Khuong(Director)Sevgi Gurkan(Executive Officer, Director, Promoter)
BoardChristy Shaffer(Director)
Board seatChau KhuongΒ· per SEC Form D
BiotechBoston, US
Darlene Deptula-Hicks(Executive Officer)Steven Prelack(Director)Chau Khuong(Director)Michael Richman(Director)Stephen S. Yoder(Executive Officer, Director)Jean-Pierre Bizzari(Director)
Board seatChau KhuongΒ· per SEC Form D Β· $16.5M raise Β· filed Jun 2016
HealthtechNew York, US
PETER THOMPSON(Director)MONA ASHIYA(Director)CARL GORDON(Director)ASA ABELIOVICH(Executive Officer, Director)
Board seatCarl GordonPeter ThompsonMona AshiyaΒ· per SEC Form D Β· $65M raise Β· filed Mar 2018
Biotech
Daniel Lawton(Executive Officer, Director)Klaus Veitinger(Executive Officer, Director)Steve Squinto(Director)Tom Beck(Executive Officer, Director)Stacey Seltzer(Director)Patrick Schwarz-Schuette(Director)
Board seatKlaus VeitingerΒ· per SEC Form D Β· $6M raise Β· filed Dec 2019
Sparrow Pharma develops targeted cardiometabolic therapeutics for patients with type 2 diabetes, focusing on cortisol regulation through HSD-1 inhibition.
BiotechHealthtechMedical DevicesPortland, US
Jonathan Root(Director)Zach Scheiner(Director)Klaus Veitinger(Director)Nanna L?neborg(Director)Peter Thompson(Director)Robert Jacks(Executive Officer, Director)
Board seatKlaus VeitingerΒ· per SEC Form D
HealthtechStamford, US
Freda Lewis-Hall(Director)Stephen Squinto(Director)Jeffrey Schwartz(Director)Deval Patrick(Director)Daniel S. Lynch(Executive Officer, Director)Saqib Islam(Executive Officer, Director)
Board seatStephen SquintoCarl GordonΒ· per SEC Form D Β· $125M raise Β· filed Apr 2019
BiotechNewark, US
Rishi Gupta(Director)Robert Jacks(Executive Officer)Karen Dawes(Director)Joseph Amprey(Executive Officer)Klaus Veitinger(Director)Thomas Beck(Director)
Board seatRishi GuptaKlaus VeitingerΒ· per SEC Form D Β· $6M raise Β· filed May 2016
BiotechCambridge, US
Iain Dukes(Executive Officer, Director)William C. Shakespeare(Director)Michael Rome(Director)Carl Gordon(Director)
Board seatCarl GordonΒ· per SEC Form D Β· $22.1M raise Β· filed Feb 2021
HealthtechKingston, US
David Bonita(Director)Keegan Harper(Director)Paul A. Stewart(Director)Sam Liang(Director)Marvin Woodall(Executive Officer, Director)John Cerminaro(Executive Officer)
Board seatDavid BonitaΒ· per SEC Form D
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)
BoardKristina Burow(Director)Ali Satvat(Director)David Schenkein(Director)Steven Elms(Director)
Board seatDavid BonitaΒ· per SEC Form D
BiotechSouth San Francisco, US
Sandra Coufal(Director)Melissa Miksch(Executive Officer)David Bonita(Director)Robert Alpern(Director)Klaus Veitinger(Director)Gerrit Klaerner(Executive Officer, Director)
Board seatKlaus VeitingerDavid BonitaΒ· per SEC Form D Β· $55.5M raise Β· filed Jul 2016
BiotechChicago, US
Rand Sutherland(Director)James Sullivan(Executive Officer, Director)
BoardBernard Davitian(Director)Uya Chuluunbaatar(Director)
Board seatJonathan SilversteinStephen SquintoMona AshiyaΒ· per SEC Form D Β· $85M raise Β· filed Sep 2021
Oakwood Village, US
David Chandler(Mr. Chandler is the Chief Financial Officer of the Issuer.)Joshua Bilenker(Director)Mark Roemer(Director)David Bonita(Director)Robert Weisskoff(Director)Philip Yang(Director)
Board seatDavid BonitaΒ· per SEC Form D Β· filed Aug 2015
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis.
HealthtechMedical DevicesMountain View, US
Matt Brokaw(CEO & President)Derrick Sung(Executive Officer)Matthew Salkeld(Executive Officer)Irina Ridley(Executive Officer)Andre Cheng(Executive Officer)Greg Young(Director)
Alterome is a clinical-stage precision oncology company developing small molecule therapies targeting mutant KRAS and AKT E17K in cancers including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancer.
BiotechHealthtechMedical DevicesSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)Thilo Schroeder(Director)Ryan B. Corcoran(Director, Promoter)Carl Gordon(Director)Arjun Goyal(Director)
Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.
BiotechDigital HealthHealthtechMedical Devices
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Carrot is a global fertility and family-building platform that provides access to fertility care, maternity support, and family-building guidance for individuals and families.
FemTechHealthtechSan Francisco, US
Congruence is a drug discovery company using protein dynamics, biophysics, machine learning, and computational chemistry to develop predictive models for disease correction.
AI & Machine LearningBiotech
Convergent provides an AI simulation platform for enterprise training and skill development.
AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Peter Bach(Executive Officer)Elizabeth Homans(Director)Rishi Gupta(Director)Justin Kao(Director)Jennifer Buechel(Executive Officer)Victor Velculescu(Executive Officer, Director, Promoter)
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical Devices
Beth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Matthew Fust(Director)Carl Gordon, Ph.D.(Director)Nancy Stagliano, Ph.D.(Director)Quehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)
BiotechSan Diego, US
Yi Liu(Executive Officer, Director)Lynn Yang(Director)Carl Gordon(Director)
BiotechSouth San Francisco, US
Tim Anderson(Director)William Rieflin(Director)Aetna Wun Trombley(Executive Officer, Director)Laurent Fischer(Director)Ming Fang(Director)Amy Bachrodt(Executive Officer)
RarePath is a biotech platform that creates pathways for scientists to develop cures for rare and ultra-rare diseases by partnering with academic researchers, biotech firms, and patient foundations to fund, license, and commercialize therapies.
Biotech
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.
AI & Machine LearningHealthtechMedical DevicesSan Diego, US
Paul Berns(Director)Joseph Papa(Director)Mark C. McKenna(Executive Officer, Director)Scott Glenn(Director)Kristina Burow(Director)Vika Brough(Executive Officer)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.